Intervention Review

You have free access to this content

Aripiprazole alone or in combination for acute mania

  1. Rachel Brown1,*,
  2. Matthew J Taylor2,
  3. John Geddes3

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group

Published Online: 17 DEC 2013

Assessed as up-to-date: 31 JUL 2013

DOI: 10.1002/14651858.CD005000.pub2


How to Cite

Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD005000. DOI: 10.1002/14651858.CD005000.pub2.

Author Information

  1. 1

    Oxford Health NHS Foundation Trust, Clinical Pharmacy Support Unit, Oxford, UK

  2. 2

    Institute of Psychiatry, King's College London, Department of Psychosis Studies, London, UK

  3. 3

    University of Oxford/Warneford Hospital, Department of Psychiatry, Oxford, UK

*Rachel Brown, Clinical Pharmacy Support Unit, Oxford Health NHS Foundation Trust, Unit 46, Sandford Lane, Kennington, Oxford, OX1 5RW, UK. rachel.brown@oxfordhealth.nhs.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 17 DEC 2013

SEARCH

[Figure 1]
Figure 1. PRISMA diagram
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Aripiprazole versus placebo, outcome: 1.1 Mean change in YMRS from baseline at three weeks.
[Figure 5]
Figure 5. Forest plot of comparison: 2 Aripiprazole versus other drug treatment, outcome: 2.2 Mean change in YMRS from baseline at week 12.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Aripiprazole versus placebo, Outcome 1 Mean change in YMRS from baseline at three weeks.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Aripiprazole versus placebo, Outcome 2 Mean change in YMRS from baseline at day four.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Aripiprazole versus placebo, Outcome 3 Mean change in YMRS from baseline week four.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Aripiprazole versus placebo, Outcome 4 Mean change in YMRS from baseline at week six.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Aripiprazole versus placebo, Outcome 5 Mean change in YMRS from baseline to week 12.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Aripiprazole versus placebo, Outcome 6 Response (≥ 50% decrease in total YMRS from baseline) at three weeks.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Aripiprazole versus placebo, Outcome 7 Response (≥ 50% decrease in total YMRS from baseline) at four weeks.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Aripiprazole versus placebo, Outcome 8 Response (≥ 50% decrease in total YMRS from baseline) at six weeks.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Aripiprazole versus placebo, Outcome 9 Remission (YMRS total score ≤ 12) at six weeks.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Aripiprazole versus placebo, Outcome 10 CGI-Bipolar Version: severity (mania)—mean change at three weeks.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Aripiprazole versus placebo, Outcome 11 CGI-Bipolar Version: severity (mania)—mean change at four weeks.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Aripiprazole versus placebo, Outcome 12 CGI-Bipolar Version: improvement (mania)—mean change at three weeks.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Aripiprazole versus placebo, Outcome 13 CGI-Bipolar Version: severity (depression)—mean change at three weeks.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Aripiprazole versus placebo, Outcome 14 CGI-Bipolar Version: severity (depression)—mean change at four weeks.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Aripiprazole versus placebo, Outcome 15 CGI-Bipolar Version: improvement (depression)—mean change at three weeks.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Aripiprazole versus placebo, Outcome 16 CGI-Bipolar Version: severity (overall)—mean change at three weeks.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Aripiprazole versus placebo, Outcome 17 CGI-Bipolar Version: severity (overall)—mean change at six weeks.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Aripiprazole versus placebo, Outcome 18 CGI-Bipolar Version: improvement (overall)—mean change at three weeks.
[Analysis 1.19]
Analysis 1.19. Comparison 1 Aripiprazole versus placebo, Outcome 19 Mean change in MADRS from baseline to week three.
[Analysis 1.20]
Analysis 1.20. Comparison 1 Aripiprazole versus placebo, Outcome 20 Mean change in PANSS total score at week three.
[Analysis 1.21]
Analysis 1.21. Comparison 1 Aripiprazole versus placebo, Outcome 21 Mean change in PANSS-hostility subscale score at week three.
[Analysis 1.22]
Analysis 1.22. Comparison 1 Aripiprazole versus placebo, Outcome 22 Mean change in PANSS cognitive subscale score at week three.
[Analysis 1.23]
Analysis 1.23. Comparison 1 Aripiprazole versus placebo, Outcome 23 Requirement for anticholinergics.
[Analysis 1.24]
Analysis 1.24. Comparison 1 Aripiprazole versus placebo, Outcome 24 Requirement for lorazepam.
[Analysis 1.25]
Analysis 1.25. Comparison 1 Aripiprazole versus placebo, Outcome 25 Numbers completing double-blind treatment.
[Analysis 1.26]
Analysis 1.26. Comparison 1 Aripiprazole versus placebo, Outcome 26 Failure to complete treatment—dropouts: adverse drug reaction.
[Analysis 1.27]
Analysis 1.27. Comparison 1 Aripiprazole versus placebo, Outcome 27 Failure to complete treatment—dropouts: lack of efficacy.
[Analysis 1.28]
Analysis 1.28. Comparison 1 Aripiprazole versus placebo, Outcome 28 Participants meeting criteria for treatment as outpatients.
[Analysis 1.29]
Analysis 1.29. Comparison 1 Aripiprazole versus placebo, Outcome 29 Simpson Angus Scale.
[Analysis 1.30]
Analysis 1.30. Comparison 1 Aripiprazole versus placebo, Outcome 30 Barnes Akathisia Scale.
[Analysis 1.31]
Analysis 1.31. Comparison 1 Aripiprazole versus placebo, Outcome 31 Abnormal Involuntary Movement Scale.
[Analysis 1.32]
Analysis 1.32. Comparison 1 Aripiprazole versus placebo, Outcome 32 Manic reaction.
[Analysis 1.33]
Analysis 1.33. Comparison 1 Aripiprazole versus placebo, Outcome 33 Hypertension.
[Analysis 1.34]
Analysis 1.34. Comparison 1 Aripiprazole versus placebo, Outcome 34 Headache.
[Analysis 1.35]
Analysis 1.35. Comparison 1 Aripiprazole versus placebo, Outcome 35 Anxiety.
[Analysis 1.36]
Analysis 1.36. Comparison 1 Aripiprazole versus placebo, Outcome 36 Insomnia.
[Analysis 1.37]
Analysis 1.37. Comparison 1 Aripiprazole versus placebo, Outcome 37 Light-headedness.
[Analysis 1.38]
Analysis 1.38. Comparison 1 Aripiprazole versus placebo, Outcome 38 Akathisia.
[Analysis 1.39]
Analysis 1.39. Comparison 1 Aripiprazole versus placebo, Outcome 39 Nausea.
[Analysis 1.40]
Analysis 1.40. Comparison 1 Aripiprazole versus placebo, Outcome 40 Dyspepsia.
[Analysis 1.41]
Analysis 1.41. Comparison 1 Aripiprazole versus placebo, Outcome 41 Vomiting.
[Analysis 1.42]
Analysis 1.42. Comparison 1 Aripiprazole versus placebo, Outcome 42 Constipation.
[Analysis 1.43]
Analysis 1.43. Comparison 1 Aripiprazole versus placebo, Outcome 43 Diarrhoea.
[Analysis 1.44]
Analysis 1.44. Comparison 1 Aripiprazole versus placebo, Outcome 44 Pain extremity.
[Analysis 1.45]
Analysis 1.45. Comparison 1 Aripiprazole versus placebo, Outcome 45 Somnolence.
[Analysis 1.46]
Analysis 1.46. Comparison 1 Aripiprazole versus placebo, Outcome 46 Tremor.
[Analysis 1.47]
Analysis 1.47. Comparison 1 Aripiprazole versus placebo, Outcome 47 EPS.
[Analysis 1.48]
Analysis 1.48. Comparison 1 Aripiprazole versus placebo, Outcome 48 Weight gain (≥ 7% increase from baseline).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Aripiprazole versus other drug treatment, Outcome 1 Mean change in YMRS from baseline at week three.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Aripiprazole versus other drug treatment, Outcome 2 Mean change in YMRS from baseline at week 12.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Aripiprazole versus other drug treatment, Outcome 3 Response ≥ 50% decrease in YMRS from baseline at week three.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Aripiprazole versus other drug treatment, Outcome 4 CGI-Bipolar Version: severity (mania)—mean change at week three.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Aripiprazole versus other drug treatment, Outcome 5 CGI-Bipolar Version: severity (mania)—mean change at week 12.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Aripiprazole versus other drug treatment, Outcome 6 CGI-Bipolar Version: severity (depression)—mean change at week 12.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Aripiprazole versus other drug treatment, Outcome 7 CGI-Bipolar Version: severity (overall)—mean change at week 12.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Aripiprazole versus other drug treatment, Outcome 8 CGI-Bipolar Version: improvement (mania)—mean change at week three.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Aripiprazole versus other drug treatment, Outcome 9 Mean change in MADRS from baseline at week three.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Aripiprazole versus other drug treatment, Outcome 10 Mean change in MADRS from baseline at week 12.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Aripiprazole versus other drug treatment, Outcome 11 Mean change in PANSS-total at week three.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Aripiprazole versus other drug treatment, Outcome 12 Mean change in PANSS-cognitive subscale score at week three.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Aripiprazole versus other drug treatment, Outcome 13 Mean change in PANSS-hostility subscale score at week three.
[Analysis 2.14]
Analysis 2.14. Comparison 2 Aripiprazole versus other drug treatment, Outcome 14 Simpson Angus Scale LOCF at week 12.
[Analysis 2.15]
Analysis 2.15. Comparison 2 Aripiprazole versus other drug treatment, Outcome 15 Barnes Akathisia Scale LOCF at week 12.
[Analysis 2.16]
Analysis 2.16. Comparison 2 Aripiprazole versus other drug treatment, Outcome 16 Abnormal Involuntary Movement Scale LOCF at week 12.
[Analysis 2.17]
Analysis 2.17. Comparison 2 Aripiprazole versus other drug treatment, Outcome 17 Akathisia.
[Analysis 2.18]
Analysis 2.18. Comparison 2 Aripiprazole versus other drug treatment, Outcome 18 Headache.
[Analysis 2.19]
Analysis 2.19. Comparison 2 Aripiprazole versus other drug treatment, Outcome 19 Tremor.
[Analysis 2.20]
Analysis 2.20. Comparison 2 Aripiprazole versus other drug treatment, Outcome 20 Numbers completing at end of week three.
[Analysis 2.21]
Analysis 2.21. Comparison 2 Aripiprazole versus other drug treatment, Outcome 21 Numbers completing the trial (at end of week 12).
[Analysis 2.22]
Analysis 2.22. Comparison 2 Aripiprazole versus other drug treatment, Outcome 22 Failure to complete treatment: dropouts—lack of efficacy at three weeks.
[Analysis 2.23]
Analysis 2.23. Comparison 2 Aripiprazole versus other drug treatment, Outcome 23 Failure to complete treatment: dropouts—adverse event at end of three weeks.